Glaukos Corp  

(Public, NYSE:GKOS)   Watch this stock  
Find more results for GKOS
31.07
-0.21 (-0.67%)
Feb 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.02 - 31.46
52 week 23.08 - 52.49
Open 31.24
Vol / Avg. 180,479.00/460,804.00
Mkt cap 1.07B
P/E     -
Div/yield     -
EPS -0.03
Shares 34.57M
Beta     -
Inst. own 113%
Feb 28, 2018
Q4 2017 Glaukos Corp Earnings Call - 4:30PM EST - Add to calendar
Jan 10, 2018
Glaukos Corp at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 3.28% 3.95%
Operating margin 1.85% 3.71%
EBITD margin - 7.83%
Return on average assets 3.57% 3.60%
Return on average equity 4.12% 4.26%
Employees 264 -
CDP Score - -

Address

229 Avenida Fabricante
SAN CLEMENTE, CA 92672-7531
United States - Map
+1-949-3679600 (Phone)
+1-949-3679984 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Officers and directors

William J. Link Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Thomas William Burns President, Chief Executive Officer and Director
Age: 56
Bio & Compensation  - Reuters
Joseph E. Gilliam Chief Financial Officer, Senior Vice President - Corporate Development
Age: 41
Bio & Compensation  - Reuters
Chris M. Calcaterra Chief Commercial Officer and Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
L. Jay Katz Chief Medical Officer
Bio & Compensation  - Reuters
Mark J. Foley Independent Director
Age: 51
Bio & Compensation  - Reuters
David F. Hoffmeister Independent Director
Age: 62
Bio & Compensation  - Reuters
Gilbert H. Kliman M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Jonathan Todd Silverstein J.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Marc A. Stapley Independent Director
Age: 46
Bio & Compensation  - Reuters